TEMPUS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations, leading to significant stock price decline [1][4]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - The issues highlighted indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, Spruce Point Capital Management issued a report raising multiple concerns about Tempus' management, operations, and financial reporting [4]. - The report pointed out that Tempus' actual AI capabilities may be overstated and that executives have ties to companies that have restated financial results [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal that warrant further scrutiny [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].